Magenta Therapeutics Debt 2024

Magenta Therapeutics Aktienanalyse

What does Magenta Therapeutics do?

Magenta Therapeutics Inc is a groundbreaking biotechnology company specializing in the development of novel therapies for serious blood disorders. The company uses a unique technology platform based on stem cell transplantation and gene editing to develop innovative therapies that have the potential to improve the lives of millions of people worldwide. Magenta Therapeutics was founded in 2016 by an experienced team of executives and scientists who had previously worked in various biotech companies. The company is headquartered in Cambridge, Massachusetts, USA and has been listed on the NASDAQ stock exchange since 2018. Its business model is based on the development and commercialization of innovative therapies for blood diseases, based on a stem cell technology platform and gene editing technology. These technologies are intended to improve the treatment of blood diseases and enhance the quality of life for patients. Magenta Therapeutics has a comprehensive portfolio of therapy candidates targeting various aspects of stem cell transplantation and gene editing. These therapies aim to reduce the risks and burdens of traditional stem cell transplantation while fully harnessing the potential of stem cell transplantation to cure or alleviate blood diseases. The company has three major business areas: stem cell therapy, gene therapy, and cell therapy. In the context of these business areas, Magenta Therapeutics has already developed several therapy candidates that are currently in various stages of clinical development. The company's work is supported by a variety of financial investors, including some of the most respected names in the biotech industry. Magenta Therapeutics is also actively involved in developing partnerships with other leading companies in the biotechnology industry to further leverage the potential of its platform technology. In conclusion, Magenta Therapeutics is a young and innovative company focused on developing and commercializing new groundbreaking therapies for blood diseases. With its approach of combining stem cell technology and gene editing, the company has the potential to improve the lives of millions of patients with blood diseases while also achieving a significant return for its investors. Magenta Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Magenta Therapeutics's Debt Structure

Magenta Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Magenta Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Magenta Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Magenta Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Magenta Therapeutics stock

What is the debt of Magenta Therapeutics this year?

Magenta Therapeutics has a debt level of -57.63 USD this year.

What was the debt of Magenta Therapeutics compared to the previous year?

The debt of Magenta Therapeutics has increased by -56.23% compared to the previous year dropped.

What are the consequences of high debt for investors in Magenta Therapeutics?

High debt can pose a risk for investors of Magenta Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Magenta Therapeutics?

Low debt means that Magenta Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Magenta Therapeutics affect the company?

An increase in debt of Magenta Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Magenta Therapeutics affect the company?

A reduction in debt of Magenta Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Magenta Therapeutics?

Some factors that can influence the debt of Magenta Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Magenta Therapeutics so important for investors?

The debts of Magenta Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Magenta Therapeutics take to change the debt?

To change the debt, Magenta Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Magenta Therapeutics pay?

Over the past 12 months, Magenta Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Magenta Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Magenta Therapeutics?

The current dividend yield of Magenta Therapeutics is .

When does Magenta Therapeutics pay dividends?

Magenta Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Magenta Therapeutics?

Magenta Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Magenta Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Magenta Therapeutics located?

Magenta Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Magenta Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Magenta Therapeutics from 12/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/1/2024.

When did Magenta Therapeutics pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Magenta Therapeutics in the year 2023?

In the year 2023, Magenta Therapeutics distributed 0 USD as dividends.

In which currency does Magenta Therapeutics pay out the dividend?

The dividends of Magenta Therapeutics are distributed in USD.